Company intelligence / Profile preview

AMSL Diabetes

Ownership: Private
Employees: ~100
Development stage: Other

Overview

AMSL Diabetes provides commercialized products for continuous glucose monitoring and insulin delivery. Their portfolio includes the Dexcom G6/G7 CGM systems and Tandem t:slim X2 insulin pump, both widely used in Australia for real-time blood glucose management. Products are fully funded for eligible Department of Veterans’ Affairs clients as of July 2023[6]. No clinical trial pipeline; all products are commercially available.

Therapeutic areas: Endocrinology
Modalities: DeviceSoftware (for diabetes management)Small molecule
Industry: Physiological Monitoring

Partnerships

Tandem Diabetes Care (distribution of t:sIim X2 pump)Glooko® (web-based data management software)

Beyond the preview

Go deeper on AMSL Diabetes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMSL Diabetes.

Explore the full profile